Weekly Recap: Q3 revenue beats estimates and Tablo rollout, high retention

Outset Medical, Inc. (NASDAQ:OM) reported Q3 2026 revenue of $33.6 million, beating estimates and rising 14% year over year. It reaffirmed full-year guidance as gross margin improved and net loss narrowed.

Previous Week Recap

• Revenue Beat, Loss Narrowed: Outset Medical reported Q3 2026 revenue of $33.6 million, beating estimates and rising 14% year over year. The company reaffirmed full-year guidance; gross margin improved and net loss narrowed.
  • 
  • 
  • 
  3 sources
• Tablo Rollout, Strong Retention: Outset Medical plans a broader release of its next-gen Tablo system over coming months and quarters. Patient retention reached at least 90% in the first 90 days as its home-dialysis base grew.
  • 
  • 
  2 sources
• Console Refresh, Sales Refocus: Outset Medical (OM) sees a console refresh opportunity across 3,000-plus systems, worth about $150 million over several years. It is refocusing sales on the 250 largest U.S. health systems.
  • 
  MarketBeat
• Margin Outlook Reaffirmed; Mix Pressure: Outset Medical (OM) reaffirmed its full-year non-GAAP gross margin outlook of low- to mid-40%. A higher share of console sales could push margins toward the lower end.
  • 
  MarketBeat